iCAD, Inc. (ICAD)

NASDAQ: ICAD · IEX Real-Time Price · USD
3.64
0.01 (0.28%)
At close: May 20, 2022 4:00 PM
3.68
0.04 (1.10%)
After-hours:May 20, 2022 4:53 PM EDT
Market Cap91.66M
Revenue (ttm)32.52M
Net Income (ttm)-13.15M
Shares Out25.18M
EPS (ttm)-0.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume169,873
Open3.68
Previous Close3.63
Day's Range3.43 - 3.74
52-Week Range2.91 - 19.00
Beta1.28
AnalystsBuy
Price Target14.45 (+297.0%)
Earnings DateMay 11, 2022

About ICAD

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calci...

IndustryHealth Care Technology
IPO DateDec 3, 1986
Employees136
Stock ExchangeNASDAQ
Ticker SymbolICAD
Full Company Profile

Financial Performance

In 2021, iCAD, Inc.'s revenue was $33.64 million, an increase of 13.27% compared to the previous year's $29.70 million. Losses were -$11.25 million, -36.14% less than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ICAD stock is "Buy." The 12-month stock price forecast is 14.45, which is an increase of 296.98% from the latest price.

Price Target
$14.45
(296.98% upside)
Analyst Consensus: Buy
Stock Forecasts

News

New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Li...

Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population...

5 days ago - GlobeNewsWire

iCAD to Present at the Spring Into Action - Best Ideas Virtual Investor Conference on May 17th, 2022

NASHUA, NH / ACCESSWIRE / May 12, 2022 / iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will presen...

1 week ago - Accesswire

Icad (ICAD) Reports Q1 Loss, Tops Revenue Estimates

Icad (ICAD) delivered earnings and revenue surprises of -40% and 0.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

iCAD Reports Financial Results for First Quarter Ended March 31, 2022

Company to host conference call and webcast today at 4:30 PM ET Company to host conference call and webcast today at 4:30 PM ET

1 week ago - GlobeNewsWire

iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11

NASHUA, N.H., April 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will r...

3 weeks ago - GlobeNewsWire

iCAD Showcases Innovative Breast Health Solutions Platform at National Consortium of Breast Centers (NCoBC) 31st Annu...

iCAD's award winning portfolio of breast health solutions to be featured at inaugural Pink Paradigm Summit, uniting clinical and advocacy leadership iCAD's award winning portfolio of breast health solut...

2 months ago - GlobeNewsWire

iCAD to Present at the 32nd Annual Oppenheimer Healthcare Conference

NASHUA, N.H., March 09, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company wi...

2 months ago - GlobeNewsWire

Icad (ICAD) Reports Q4 Loss, Lags Revenue Estimates

Icad (ICAD) delivered earnings and revenue surprises of -54.55% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2021

Launched ProFound AI® Risk, the world's first clinical decision support tool for short term breast cancer risk estimation

2 months ago - GlobeNewsWire

Analysts Estimate Icad (ICAD) to Report a Decline in Earnings: What to Look Out for

Icad (ICAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

iCAD to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28

NASHUA, N.H., Feb. 14, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will re...

3 months ago - GlobeNewsWire

iCAD's Breast AI Platform Earns U.S. Department of Defense Authorization to Operate

Leading-edge breast cancer detection platform meets stringent U.S. government security thresholds required for use across military healthcare facilities Leading-edge breast cancer detection platform mee...

3 months ago - GlobeNewsWire

iCAD Announces the Appointment of New Members to its Board of Directors

Dana Brown and Timothy Norris Irish offer extensive experience in technology, women's breast health and unique global perspectives Dana Brown and Timothy Norris Irish offer extensive experience in techn...

4 months ago - GlobeNewsWire

7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now

These cheap stocks under $10 are poised to rally in the new, more friendly macro environment that's in place as 2022 unfolds. The post 7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now appeared f...

Other symbols:AYROBNGOQUBTSFETSOLO
4 months ago - InvestorPlace

iCAD to Participate at the 11th Annual LifeSci Partners Virtual Corporate Access Event

Company's President and incoming CEO to participate in a panel discussion titled “Med Tech / Digital Tools: What's the Mindset for 2022?” on January 5, 2022 at 2:00 pm ET Company's President and incomin...

4 months ago - GlobeNewsWire

First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States

Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor

5 months ago - GlobeNewsWire

iCAD to Participate at the Imagine AI + Healthcare Investor Summit

NASHUA, N.H., Dec. 06, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Ste...

5 months ago - GlobeNewsWire

iCAD Announces CEO Transition

Stacey Stevens Appointed as President and CEO and will Join the Board of Directors in 2022, Michael Klein to remain Chairman of iCAD Board Stacey Stevens Appointed as President and CEO and will Join the...

5 months ago - GlobeNewsWire

iCAD to Participate in the 12th Annual Craig-Hallum Alpha Select Conference

NASHUA, N.H., Nov. 11, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will pa...

6 months ago - GlobeNewsWire

Icad (ICAD) Reports Q3 Loss, Misses Revenue Estimates

Icad (ICAD) delivered earnings and revenue surprises of 0.00% and -0.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Earnings Preview: Icad (ICAD) Q3 Earnings Expected to Decline

Icad (ICAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

7 Best Stocks to Buy on the Dip in October

Market volatility has provided investors with some prime opportunities. These high-quality stocks to buy have very attractive price points.

Other symbols:AGATVILRCXMUPLTRSWIR
7 months ago - InvestorPlace

iCAD Unveils Next Generation Technologies at Journées Francophones de Radiologie (October 8-11, Paris, France)

Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions

7 months ago - GlobeNewsWire

iCAD Launches Revolutionary Short-term Personalized Risk Assessment Solution for 3D Mammography

Latest generation of ProFound AI Risk offers greater accuracy and ethnically inclusive precision screening

7 months ago - GlobeNewsWire

iCAD to Host Educational Roundtable to Help Clinicians and Facilities Recover from COVID-19 Impact

Leading experts to discuss novel AI technology helping them overcome pandemic-related challenges including substantial mammography backlog Leading experts to discuss novel AI technology helping them ove...

8 months ago - GlobeNewsWire